Pfizer, Inc. (PFE) Shares Sold by Bremer Trust National Association
Bremer Trust National Association lowered its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 5.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 60,266 shares of the biopharmaceutical company’s stock after selling 3,641 shares during the period. Bremer Trust National Association’s holdings in Pfizer were worth $2,024,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 1.7% during the 1st quarter. Fisher Asset Management LLC now owns 32,759,530 shares of the biopharmaceutical company’s stock worth $1,120,704,000 after buying an additional 554,777 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Pfizer by 1.2% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock worth $1,069,433,000 after buying an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of Pfizer by 0.9% during the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock worth $844,431,000 after buying an additional 228,405 shares in the last quarter. Boston Partners raised its holdings in shares of Pfizer by 7.3% during the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after buying an additional 1,649,801 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Pfizer by 1.0% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 17,376,931 shares of the biopharmaceutical company’s stock worth $594,465,000 after buying an additional 169,073 shares in the last quarter. 69.00% of the stock is owned by institutional investors.
In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 over the last three months. 0.06% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/18/pfizer-inc-pfe-shares-sold-by-bremer-trust-national-association.html.
A number of equities analysts have recently commented on the company. BMO Capital Markets reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Thursday. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, August 2nd. Credit Suisse Group cut Pfizer from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. Finally, Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $37.83.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.099% during midday trading on Monday, hitting $35.325. The company had a trading volume of 3,970,660 shares. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $35.84. The firm’s 50 day moving average is $33.64 and its 200 day moving average is $33.53. The company has a market capitalization of $210.09 billion, a P/E ratio of 25.841 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.64 earnings per share. Equities research analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.62%. Pfizer’s payout ratio is presently 94.12%.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.